A federal judge has rejected the latest effort by out-of-state applicants to stop New York state from licensing adult-use marijuana stores, ruling in part that constitutional free-trade protections don’t apply to federally illegal marijuana.
The Drug Enforcement Administration should go beyond health regulators’ marijuana rescheduling recommendation and deschedule the drug entirely, top Democratic U.S. senators wrote in a letter.
An Oregon cannabis company withdrew its federal lawsuit challenging a state ban on interstate marijuana commerce, court records show.
Two legal cases have realistic chances of success, meaning cannabis operators should consider filing amended federal tax returns claiming refunds.
U.S. Department of Justice attorneys asked a federal judge on Tuesday to dismiss a lawsuit filed by four marijuana companies challenging federal prohibition.
Here’s how marijuana rescheduling could impact medical practitioners working in the cannabis space.
The Biden administration’s push to reclassify marijuana under federal law would not by itself open the door for pharmaceutical companies to seize control of the $34 billion legal U.S. cannabis industry.
State-regulated medical cannabis programs and illicit users are at least in part to thank for the Biden administration’s recommendation that marijuana be moved from Schedule 1 to Schedule 3 of the Controlled Substances Act.
The Biden administration on late Friday released the unredacted exchange between federal authorities recommending marijuana be rescheduled.
Attorneys general from 12 states sent a letter to the head of the U.S. Drug Enforcement Administration to “encourage” the DEA to reschedule marijuana.
From legislative and regulatory changes to market sensitivity and price stabilization to M&A dynamics, it will be crucial to remain cautious of hurdles that the marijuana sector will face and stay on top of the five areas that are expected to shape the industry in 2024.
